Perspective: The Precision-Oncology Illusion

September 12, 2016

(Nature) – When patients with diverse, relapsed cancers are given drugs based on biological markers, only around 30% respond at all, and the median progression-free survival is just 5.7 months. Multiplying the percentage of patients receiving targeted therapies by this response rate, I estimate that precision oncology will benefit around 1.5% of patients with relapsed and refractory solid tumours. It is on this tiny proportion of patients that the hopes for precision oncology have been built.